Screener
Nurix Therapeutics, Inc. NRIX Q2 2026 earnings
Reported July 9, 2026 · Before market open
Revenue$9.0MMiss by $6.2M
EPS-$0.81Miss by $0.08
Revenue estimate$15.3M
EPS estimate-$0.73
“The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field, Our global collaboration with Roche, an industry leader, validates both the differentiated clinical profile of bexobrutideg in malignant hematology and its broader potential in immunology and inflammation. The co-development, co-commercialization structure of the agreement allows Nurix to pursue multiple opportunities in significant markets in both oncology and autoimmune disease with financial strength and global reach.”
Next report
Oct 8, 2026 (in 2 months)Revenue estimate$19.2M
EPS estimate-$0.65
Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Nurix Therapeutics, Inc. report Q2 2026 earnings?
- Nurix Therapeutics, Inc. (NRIX) reported Q2 2026 earnings on July 9, 2026 before market open.
- What were Nurix Therapeutics, Inc.'s Q2 2026 revenue and EPS?
- Nurix Therapeutics, Inc. reported revenue of $9.0M and eps of $-0.81 for Q2 2026.
- Did Nurix Therapeutics, Inc. beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $15.3M by $6.2M. EPS missed the consensus estimate of $-0.73 by $0.08.
- How did Nurix Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 79.5% from $44.1M a year earlier and eps declined 55.8% from $-0.52.
- Where can I find Nurix Therapeutics, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001549595-26-000038) and the 10-Q periodic report (0001549595-26-000040) directly on SEC EDGAR. The filing index links above go to sec.gov.
